LOS ANGELES, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”), clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that management will be participating in the upcoming Jefferies London Healthcare Conference and the Piper Sandler Virtual Healthcare Conference.Conference details can be found below.Jefferies London Healthcare ConferenceFormat: ... Read More

LOS ANGELES, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Scott Giacobello, CPA, to the role of Chief Financial Officer (CFO) and Treasurer, effective November 28, 2021.   Most recently, Mr. Giacobello was ... Read More

LOS ANGELES, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Loretta M. Itri, M.D., FACP®, to the role of Chief Medical Officer (CMO). Dr. Itri’s extensive career spans clinical ... Read More

Results Published from First Clinical Trial in this Rare DiseaseLOS ANGELES, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the publication of “nab-Sirolimus for Patients with Malignant Perivascular Epithelioid Cell Tumors”, ... Read More

LOS ANGELES, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”), a privately-held clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., will present at H.C. Wainwright’s 2nd Annual Precision Oncology Conference, which will be held virtually.Presentation Information:Date: Wednesday, October ... Read More

- Poster Presentation to go Live on October 7, 2021 at 9 a.m. ET and on Demand at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics -LOS ANGELES, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, ... Read More

LOS ANGELES, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Brendan Delaney to the role of Chief Operating Officer (COO). Brendan has had an established career in oncology-focused commercial leadership ... Read More

 Shares of Aadi to commence trading on the Nasdaq Capital Market on August 27, 2021 under ticker symbol “AADI”Concurrent $155 million PIPE financing is backed by leading life science investors led by Acuta Capital Partners and KVP Capital and included Avoro Capital Advisors; Avoro Ventures; Venrock Healthcare Capital Partners; BVF Partners, L.P.; Vivo Capital; Alta Bioequities, L.P.; Rock Springs Capital; RTW Investments, ... Read More

FDA grants Priority Review and sets PDUFA target action date of November 26, 2021LOS ANGELES, July 26, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”), a privately-held, clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that the U.S. Food and Drug ... Read More